par Piccart-Gebhart, Martine ;Bertelsen, K;Stuart, G;Cassidy, J;Mangioni, C;Simonsen, E;James, K;Kaye, S;Vergote, Ignace;Blom, R;Grimshaw, R;Atkinson, R;Swenerton, K;Trope, C;Nardi, M;Kaern, J;Tumolo, Salvatore;Timmers, P;Roy, J A;Lhoas, F;Lidvall, B;Bacon, M;Birt, A;Andersen, J E;Zee, B;Paul, J;Pecorelli, Sërgio;Baron, Benoît;Mcguire, William Patrick
Référence International journal of gynecological cancer, 13 Suppl 2, page (144-148)
Publication Publié, 2003
Référence International journal of gynecological cancer, 13 Suppl 2, page (144-148)
Publication Publié, 2003
Article révisé par les pairs
Résumé : | Two independent and consecutive randomized clinical trials, conducted by the American Gynecological Oncology Group and by an European-Canadian Intergroup, have shown superiority, in clinical response rate, progression-free survival, and overall survival, of a cisplatin-paclitaxel regimen over cisplatin-cyclophosphamide given as first-line chemotherapy for women with advanced epithelial ovarian cancer. The results of these studies, published with a median follow-up of about 3 years, have been updated with a 6.5-year follow-up: In each case, an 11% absolute gain in survival favoring the paclitaxel arm is shown; this advantage remains both statistically and clinically significant and supports a role for paclitaxel in frontline chemotherapy for advanced ovarian cancer. |